A potent and selective antimicrobial poly(amidoamine) dendrimer conjugate with LED209 targeting QseC receptor to inhibit the virulence genes of gram negative bacteria

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 329-339

  Xue, Xiao Yan ^a   Mao, Xing Gang ^b   Li, Zhi ^a   Chen, Zhou ^a   Zhou, Ying ^a   Hou, Zheng ^a   Li, Ming Kai ^a   Meng, Jing Ru ^a   Luo, Xiao Xing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antimicrobial resistance; Gram negative bacteria; LED209; Poly(amidoamine) dendrimer; QseC

Indexed keywords

ANTIBIOTICS; ANTIMICROBIAL AGENTS; CYTOTOXICITY; DENDRIMERS; GENE EXPRESSION; MAMMALS;

ANTIMICROBIAL RESISTANCES; GRAM-NEGATIVE BACTERIA; LED209; POLYAMIDOAMINE DENDRIMERS; QSEC;

BACTERIA;

BACTERIAL PROTEIN; DENDRIMER; POLYAMIDOAMINE; QSEC PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; LED209; PAMAM STARBURST; QSCR PROTEIN, PSEUDOMONAS AERUGINOSA; REPRESSOR PROTEIN; SULFONAMIDE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL VIRULENCE; CARBON NUCLEAR MAGNETIC RESONANCE; CYTOTOXICITY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZETA POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; VIRULENCE;

BACTERIA (MICROORGANISMS); MAMMALIA; NEGIBACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DENDRIMERS; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; HUMANS; INFECTION; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; REPRESSOR PROTEINS; SULFONAMIDES; VIRULENCE;

EID: 84922787234     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.016     Document Type: Article

References (35)

1. Curcio D. Multidrug-resistant gram-negative bacterial infections: are you ready for the challenge?. Curr Clin Pharmacol 2014, 9:27-38.
2. Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol 2011, 11:433-438.
3. Alcorn K., Gerrard J., Macbeth D., Steele M. Seasonal variation in health care-associated bloodstream infection: increase in the incidence of gram-negative bacteremia in nonhospitalized patients during summer. Am J Infect Control 2013, 41:1205-1208.
4. Sandora T.J., Goldmann D.A. Preventing lethal hospital outbreaks of antibiotic-resistant bacteria. N Engl J Med 2012, 367:2168-2170.
5. Apisarnthanarak A., Hsu L.Y., Khawcharoenporn T., Mundy L.M. Carbapenem-resistant gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?. Expert Rev Anti-Infect Ther 2013, 11:147-157.
6. Boucher H.W., Talbot G.H., Benjamin D.K., Bradley J., Guidos R.J., Jones R.N., et al. 10×'20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:1685-1694.
7. Huynh L., Neale C., Pomes R., Allen C. Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine 2012, 8:20-36.
8. Klajnert B., Bryszewska M. BIO-Dendrimer 2008: symposium on biomedical properties and applications of dendrimers-Lodz, Poland. Nanomedicine 2009, 5:2-3.
9. Wang R.E., Costanza F., Niu Y., Wu H., Hu Y., Hang W., et al. Development of self-immolative dendrimers for drug delivery and sensing. J Control Release 2012, 159:154-163.
10. Gupta U., Agashe H.B., Asthana A., Jain N.K. A review of in vitro-in vivo investigations on dendrimers: the novel nanoscopic drug carriers. Nanomedicine 2006, 2:66-73.
11. Mintzer M.A., Dane E.L., O'Toole G.A., Grinstaff M.W. Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol Pharm 2012, 9:342-354.
12. Campoccia D., Montanaro L., Arciola C.R. A review of the biomaterials technologies for infection-resistant surfaces. Biomaterials 2013, 34:8533-8554.
13. Xue X., Chen X., Mao X., Hou Z., Zhou Y., Bai H., et al. Amino-terminated generation 2 poly(amidoamine) dendrimer as a potential broad-spectrum, nonresistance-inducing antibacterial agent. AAPS J 2013, 15:132-142.
14. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 1996, 30:53-65.
15. Lopez A.I., Reins R.Y., McDermott A.M., Trautner B.W., Cai C. Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. Mol Biosyst 2009, 5:1148-1156.
16. Calabretta M.K., Kumar A., McDermott A.M., Cai C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules 2007, 8:1807-1811.
17. Jevprasesphant R., Penny J., Attwood D., McKeown N.B., D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 2003, 20:1543-1550.
18. Kumar A., Yellepeddi V.K., Vangara K.K., Strychar K.B., Palakurthi S. Mechanism of gene transfection by polyamidoamine (PAMAM) dendrimers modified with ornithine residues. J Drug Target 2011, 19:770-780.
19. Hsien K.C., Chen H.T., Chen Y.C., Chen Y.L., Lu C.Y., Kao C.L. Pyridoxal 5'-phosphate binding in lysine-modified PAMAM dendrimers: a biomimetic approach. Org Lett 2009, 11:3526-3529.
20. Janaszewska A., Ciolkowski M., Wrobel D., Petersen J.F., Ficker M., Christensen J.B., et al. Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligible toxicity against three rodent cell-lines. Nanomedicine 2013, 9:461-464.
21. Ciolkowski M., Petersen J.F., Ficker M., Janaszewska A., Christensen J.B., Klajnert B., et al. Surface modification of PAMAM dendrimer improves its biocompatibility. Nanomedicine 2012, 8:815-817.
22. Rasko D.A., Moreira C.G., Li de R., Reading N.C., Ritchie J.M., Waldor M.K., et al. Targeting QseC signaling and virulence for antibiotic development. Science 2008, 321:1078-1080.
23. Xue X.Y., Zhou Y., Chen Y.Y., Meng J.R., Jia M., Hou Z., et al. Promoting effects of chemical permeation enhancers on insulin permeation across TR146 cell model of buccal epithelium in vitro. Drug Chem Toxicol 2012, 35:199-207.
24. Reynolds R., Shackcloth J., Felmingham D., MacGowan A. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme. J Antimicrob Chemother 2003, 52:925-930.
25. Radzishevsky I.S., Rotem S., Bourdetsky D., Navon-Venezia S., Carmeli Y., Mor A. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol 2007, 25:657-659.
26. Rozgonyi F., Szabo D., Kocsis B., Ostorhazi E., Abbadessa G., Cassone M., et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr Med Chem 2009, 16:3996-4002.
27. Bai H., You Y., Yan H., Meng J., Xue X., Hou Z., et al. Antisense inhibition of gene expression and growth in gram-negative bacteria by cell-penetrating peptide conjugates of peptide nucleic acids targeted to rpoD gene. Biomaterials 2012, 33:659-667.
28. Shi X., Majoros I.J., Patri A.K., Bi X., Islam M.T., Desai A., et al. Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis. Analyst 2006, 131:374-381.
29. Peterson J., Allikmaa V., Subbi J., Pehk T., Lopp M. Structural deviations in poly(amidoamine) dendrimers: a MALDI-TOF MS analysis. Eur Polym J 2003, 39:33-42.
30. Arciola C.R., Campoccia D., Speziale P., Montanaro L., Costerton J.W. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 2012, 33:5967-5982.
31. Kim Y., Klutz A.M., Jacobson K.A. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem 2008, 19:1660-1672.
32. Okuda T., Kawakami S., Maeie T., Niidome T., Yamashita F., Hashida M. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release 2006, 114:69-77.
33. Moscicki A.B., Kaul R., Ma Y., Scott M.E., Daud I.I., Bukusi E.A., et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J Acquir Immune Defic Syndr 2012, 59:134-140.
34. Carballo-Dieguez A., Giguere R., Dolezal C., Chen B.A., Kahn J., Zimet G., et al. "Tell Juliana": acceptability of the candidate microbicide VivaGel(R) and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study. AIDS Behav 2012, 16:1761-1774.
35. Price C.F., Tyssen D., Sonza S., Davie A., Evans S., Lewis G.R., et al. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 2011, 6:e24095.